Life-threatening adverse drug reactions causing - respiratory depression

Description

Drug-induced respiratory depression most classically results from opioid or sedative-hypnotic (benzodiazepine, barbiturate) central nervous system depression of the brainstem respiratory drive - a dose-dependent effect substantially amplified when these drug classes are combined, given their synergistic (not merely additive) depressant effect

A significant cause of preventable drug-related death, particularly relevant to the ongoing opioid-related mortality burden and to combined opioid-benzodiazepine prescribing, which carries markedly elevated risk over either agent alone

Opioids directly suppress brainstem respiratory centre responsiveness to rising CO2, reducing respiratory rate and tidal volume; benzodiazepines/sedatives potentiate GABA-mediated CNS depression - when combined, these mechanisms interact synergistically rather than simply additively, producing respiratory depression risk disproportionately greater than either drug's individual risk would suggest

Respiratory rate and sedation level monitoring (not oxygen saturation alone, which can remain falsely reassuring with supplemental oxygen despite significant hypoventilation) is the more sensitive bedside assessment for evolving opioid-induced respiratory depression
Risk stratification (opioid-naive status, renal/hepatic impairment affecting clearance, concurrent sedative use, obstructive sleep apnoea) should guide dosing caution and monitoring intensity

Naloxone for confirmed or strongly suspected opioid-induced respiratory depression - titrated to reverse respiratory depression while minimising precipitated withdrawal, with repeat dosing/infusion given naloxone's shorter half-life than many opioids risking re-sedation
Flumazenil for benzodiazepine-induced respiratory depression is used cautiously, given seizure risk in dependent patients, and is not routinely recommended for mixed/unknown overdose
Avoiding concurrent opioid-benzodiazepine prescribing where possible, given the synergistic risk

Combined opioid-benzodiazepine prescribing risk (a major, largely preventable mortality driver), naloxone's shorter half-life than most opioids (re-sedation risk requiring observation/repeat dosing), oxygen saturation as a falsely reassuring monitoring parameter with supplemental oxygen

Oxygen saturation monitoring alone can be falsely reassuring in evolving opioid-induced respiratory depression when supplemental oxygen is being given, since saturation can remain normal despite significantly reduced ventilation - respiratory rate and sedation level are more sensitive, and should be actively monitored rather than relying on pulse oximetry alone

6 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.